Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

They dance in kitchens and in meadows frothy with flowers. They dance at weddings. They dance while fireworks bloom in dark ...